Regulations.gov document
Reference 6 - Preclinical Assessment of Investigational Cellular and Gene Therapy Products…
Supporting & Related Material · FDA-2020-D-2101 · posted May 17, 2022
Key facts
| Document ID | FDA-2020-D-2101-0031 |
|---|---|
| Title | Reference 6 - Preclinical Assessment of Investigational Cellular and Gene Therapy Products Guidance for Industry re Human Gene Therapy for Neurodegenerative Diseases; Draft Guidance for Industry |
| Document type | Supporting & Related Material |
| Subtype | Background Material |
| Agency | FDA |
| Docket | FDA-2020-D-2101 |
| Posted | May 17, 2022 |
At a glance
- 10–99 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: